Phototherapy Market Research Report—Forecast till 2027

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 1.2 MARKET ATTRACTIVENESS ANALYSIS 1.2.1 GLOBAL PHOTOTHERAPY MARKET, BY PRODUCT 1.2.1.1 GLOBAL PHOTOTHERAPY MARKET, BY CONVENTIONAL PHOTOTHERAPY EQUIPMENT 1.2.3 GLOBAL PHOTOTHERAPY MARKET, BY RADIATION 1.2.4 GLOBAL PHOTOTHERAPY MARKET, BY APPLICATION 1.2.4.1 GLOBAL PHOTOTHERAPY MARKET, BY SKIN DISEASE TREATMENT 1.2.4.2 GLOBAL PHOTOTHERAPY MARKET, BY STERILIZATION 1.2.5 GLOBAL PHOTOTHERAPY MARKET, BY END USER 1.2.6 GLOBAL PHOTOTHERAPY MARKET, BY REGION 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 2.2 RESEARCH OBJECTIVE 2.3 MARKET STRUCTURE 3 RESEARCH METHODOLOGY 3.1 RESEARCH PROCESS 3.2 PRIMARY RESEARCH 3.3 SECONDARY RESEARCH 3.4 MARKET SIZE ESTIMATION 3.5 FORECAST MODEL 3.6 LIST OF ASSUMPTIONS & LIMITATIONS 4 MARKET DYNAMICS 4.1 INTRODUCTION 4.2 DRIVERS 4.2.1 INCREASING PREVALENCE OF SEVERE SKIN DISEASES 4.2.2 RISING NUMBER OF PRETERM AND LOW-WEIGHT BIRTHS 4.2.3 RISING ADOPTION OF LED-BASED PHOTOTHERAPY EQUIPMENT 4.2.4 DRIVERS IMPACT ANALYSIS 4.3 RESTRAINTS 4.3.1 DIFFERENTIAL AWARENESS AND AVAILABILITY BETWEEN COUNTRIES 4.3.2 ISSUES IN VENTURE CAPITAL, STARTUPS, AND COLLABORATIONS 4.3.3 RESTRAINTS IMPACT ANALYSIS 4.4 OPPORTUNITIES 4.4.1 RISING ADOPTION OF HOME PHOTOTHERAPY FOR THE TREATMENT OF SKIN DISEASES 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN 5.1.1 R&D AND DESIGNING 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION & SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER’S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 BARGAINING POWER OF BUYERS 5.2.4 THREAT OF SUBSTITUTES 5.2.5 RIVALRY 5.3 IMPACT OF COVID-19 ON THE GLOBAL PHOTOTHERAPY MARKET 5.3.1 OVERVIEW 5.3.2 DEMAND-SUPPLY ANALYSIS 5.3.3 IMPACT ON PRODUCTION 6 GLOBAL PHOTOTHERAPY MARKET, BY PRODUCT 6.1 INTRODUCTION 6.2 CONVENTIONAL PHOTOTHERAPY EQUIPMENT 6.2.1 CONVENTIONAL PHOTOTHERAPY EQUIPMENT WITH FLUORESCENT LAMP 6.2.2 CONVENTIONAL PHOTOTHERAPY EQUIPMENT WITH COMPACT FLUORESCENT LAMPS 6.2.2.1 FULL-BODY PHOTOTHERAPY EQUIPMENT 6.2.2.2 PARTIAL-BODY PHOTOTHERAPY EQUIPMENT 6.3 LED PHOTOTHERAPY EQUIPMENT 6.4 FIBEROPTIC PHOTOTHERAPY EQUIPMENT 6.5 GERMICIDAL LAMPS 6.6 ACCESSORIES 7 GLOBAL PHOTOTHERAPY MARKET BY RADIATION 7.1 OVERVIEW 7.2 UVA 7.3 UVB 7.4 UVC 8 GLOBAL PHOTOTHERAPY MARKET, BY APPLICATION 8.1 OVERVIEW 8.2 SKIN DISEASE TREATMENT 8.2.1 PSORIASIS 8.2.2 VITILIGO 8.2.3 ECZEMA 8.2.4 OTHERS 8.3 NEONATAL JAUNDICE MANAGEMENT 8.4 STERILIZATION 8.4.1 HOSPITAL SERVICES 8.4.2 EQUIPMENT 9 GLOBAL PHOTOTHERAPY MARKET BY END USER 9.1 OVERVIEW 9.2 HOSPITAL & CLINIC 9.3 DERMATOLOGY CENTER 9.4 HOMECARE 9.5 LIST OF HOSPITALS AND CLINICS IN THE US 10 GLOBAL PHOTOTHERAPY MARKET, BY REGION 10.1 INTRODUCTION 10.2 AMERICAS 10.2.1 NORTH AMERICA 10.2.1.1 US 10.2.1.2 CANADA 10.2.2 LATIN AMERICA 10.3 EUROPE 10.3.1 WESTERN EUROPE 10.3.1.1 GERMANY 10.3.1.2 FRANCE 10.3.1.3 UK 10.3.1.4 ITALY 10.3.1.5 SPAIN 10.3.1.6 REST OF WESTERN EUROPE 10.3.2 EASTERN EUROPE 10.4 ASIA-PACIFIC 10.4.1 CHINA 10.4.2 INDIA 10.4.3 JAPAN 10.4.4 AUSTRALIA 10.4.5 SOUTH KOREA 10.4.6 REST OF ASIA-PACIFIC 10.5 MIDDLE EAST & AFRICA 10.5.1 MIDDLE EAST 10.5.2 ISRAEL 10.5.3 AFRICA 11 COMPETITIVE LANDSCAPE 11.1 COMPETITIVE OVERVIEW 11.2 COMPETITOR DASHBOARD 11.3 MARKET SHARE ANALYSIS 11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL PHOTOTHERAPY MARKET 11.5 COMPETITIVE BENCHMARKING 11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL PHOTOTHERAPY MARKET 11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 11.7.1 CONTRACTS & AGREEMENTS 11.7.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES 11.7.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES 11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 11.8.1 SALES & OPERATING INCOME 11.8.2 R&D EXPENDITURE 11.8.3 CURRENT CAPITAL MARKET RATIO 12 COMPANY PROFILES 12.1 SIGNIFY HOLDING 12.1.1 COMPANY OVERVIEW 12.1.2 FINANCIAL OVERVIEW 12.1.3 PRODUCTS/SERVICES OFFERED 12.1.4 KEY DEVELOPMENTS 12.1.5 SWOT ANALYSIS 12.1.6 KEY STRATEGIES 12.2 GE HEALTHCARE 12.2.1 COMPANY OVERVIEW 12.2.2 FINANCIAL OVERVIEW 12.2.3 PRODUCTS/SERVICES OFFERED 12.2.4 KEY DEVELOPMENTS 12.2.5 SWOT ANALYSIS 12.2.6 KEY STRATEGIES 12.3 NATUS MEDICAL INCORPORATED 12.3.1 COMPANY OVERVIEW 12.3.2 FINANCIAL OVERVIEW 12.3.3 PRODUCTS/SERVICES OFFERED 12.3.4 KEY DEVELOPMENTS 12.3.5 SWOT ANALYSIS 12.3.6 KEY STRATEGIES 12.4 HERBERT WALDMANN GMBH & CO. KG 12.4.1 COMPANY OVERVIEW 12.4.2 FINANCIAL OVERVIEW 12.4.3 PRODUCTS/SERVICES OFFERED 12.4.4 KEY DEVELOPMENTS 12.4.5 SWOT ANALYSIS 12.4.6 KEY STRATEGIES 12.5 PHOENIX MEDICAL SYSTEMS (P) LTD 12.5.1 COMPANY OVERVIEW 12.5.2 FINANCIAL OVERVIEW 12.5.3 PRODUCTS/SERVICES OFFERED 12.5.4 KEY DEVELOPMENTS 12.5.5 SWOT ANALYSIS 12.5.6 KEY STRATEGIES 12.6 ATOM MEDICAL CORPORATION 12.6.1 COMPANY OVERVIEW 12.6.2 FINANCIAL OVERVIEW 12.6.3 PRODUCTS/SERVICES OFFERED 12.6.4 KEY DEVELOPMENTS 12.6.5 SWOT ANALYSIS 12.6.6 KEY STRATEGIES 12.7 NATIONAL BIOLOGICAL CORPORATION 12.7.1 COMPANY OVERVIEW 12.7.2 FINANCIAL OVERVIEW 12.7.3 PRODUCTS/SERVICES OFFERED 12.7.4 KEY DEVELOPMENTS 12.7.5 SWOT ANALYSIS 12.7.6 KEY STRATEGIES 12.8 SOLARC SYSTEMS INC. 12.8.1 COMPANY OVERVIEW 12.8.2 FINANCIAL OVERVIEW 12.8.3 PRODUCTS/SERVICES OFFERED 12.8.4 KEY DEVELOPMENTS 12.8.5 SWOT ANALYSIS 12.8.6 KEY STRATEGIES 12.9 THE DAAVLIN COMPANY 12.9.1 COMPANY OVERVIEW 12.9.2 FINANCIAL OVERVIEW 12.9.3 PRODUCTS/SERVICES OFFERED 12.9.4 KEY DEVELOPMENTS 12.9.5 SWOT ANALYSIS 12.9.6 KEY STRATEGIES 12.10 STRATA SKIN SCIENCES, INC. 12.10.1 COMPANY OVERVIEW 12.10.2 FINANCIAL OVERVIEW 12.10.3 PRODUCTS/SERVICES OFFERED 12.10.4 KEY DEVELOPMENTS 12.10.5 SWOT ANALYSIS 12.10.6 KEY STRATEGIES 13 APPENDIX 13.1 REFERENCES